证券代码：301363 证券简称：美好医疗 公告编号：2023-053 深圳市美好创亿医疗科技股份有限公司 第二届监事会第五次会议决议公告 二、监事会会议审议情况 经全体与会监事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于 2023 年半年度报告全文及其摘要的议案》 经核查，监事会认为：董事会编制和审核公司《2023年半年度报告全文及其 摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的相关公 告。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 （二）审议通过《关于 2023 年半年度募集资金存放与使用情况的专项报告 的议案》 1 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届监事会 第五次会议通知于2023年8月18日以书面、电话等方式送达全体监事，并于2023 年8月28 ...

关于深圳市美好创亿医疗科技股份有限公司 2023 年半年度持续督导跟踪报告 东兴证券股份有限公司 | 保荐机构名称：东兴证券股份有限公司 | 被保荐公司简称：美好医疗（股票代码 301363） | | --- | --- | | 保荐代表人姓名：于洁泉 | 联系电话：010-66555013 | | 保荐代表人姓名：李靖宇 | 联系电话：010-66555013 | | 公司及股东承诺事项 | 是否履 | 未履行承诺的原因 | | --- | --- | --- | | | 行承诺 | 及解决措施 | | 1.公司股东关于所持股份的流通限制及自愿锁定股份、持 | 是 | 不适用 | | 股及减持意向的承诺 | | | | 2.公司及公司控股股东、实际控制人、董事（独立董事除 外）、高级管理人员关于上市后三年内稳定股价的承诺 | 是 | 不适用 | | 3.公司及公司控股股东、实际控制人、董事、监事、高级管 | | | | 理人员关于招股说明书无虚假记载、误导性陈述或者重大 | 是 | 不适用 | | 遗漏的承诺 | | | 2 | 公司及股东承诺事项 | 是否履 | 未履行承诺的原因 | | --- | -- ...

证券代码：301363 证券简称：美好医疗 公告编号：2023-052 深圳市美好创亿医疗科技股份有限公司 第二届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会 第五次会议通知于2023年8月18日以书面、电话等方式送达全体董事，并于2023 年8月28日以现场结合通讯的方式在公司会议室召开。本次会议由董事长熊小川 先生主持，会议应到董事7人，实际参会董事7人，其中王建新先生以通讯方式出 席。经全体与会董事确认，本次会议的召集、召开以及审议程序符合《中华人民 共和国公司法》《公司章程》和《董事会议事规则》等有关规定，会议形成的决 议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于 2023 年半年度报告全文及其摘要的议案》 公司董事会认为：《2023年半年度报告》及《2023年半年度报告摘要》真实、 准确、完整地反映了公司2023年半年度的财务状况和经营成果，不存在虚假记载、 误导性陈述和重大遗漏。 具体内容详见公司于同日在巨潮资讯网 ...

2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：深圳市美好创亿医疗科技股份有限公司 单位：人民币万元 | 非经营性资金占用 | | 占用方与上市公 | 上市公司核算 | 2023年半年度期初 | 2023年半年度占用 | 2023年半年度占用 | 2023年半年度偿还 | 2023年半年度期末 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用方名称 | 司的关联关系 | 的会计科目 | 占用资金余额 | 累计发生金额 （不含利息） | 资金的利息 （如有） | 累计发生金额 | 占用资金余额 | 占用形成原因 | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 其他关联方及其附属企业 | | | ...

深圳市美好创亿医疗科技股份有限公司 关于2023年上半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和深 圳证券交易所印发的《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》（深证上〔2022〕14 号）等相关规定，深圳市美好创亿医疗 科技股份有限公司（以下简称"公司"或"本公司"）编制了《关于 2023 年半年 度募集资金存放与使用情况的专项报告》，现将公司 2023 年半年度募集资金存放 与使用情况说明如下： 一、 募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2022〕1441 号），本公司由主承 销商东兴证券股份有限公司采用余额包销方式，向社会公众公开发行人民币普通 股（A 股）股票 4,427.00 万股，发行价为 ...

证券代码：301363 证券简称：美好医疗 公告编号：2023-0 57 深圳市美好创亿医疗科技股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称公司或美好医疗）于2023 年8月28日分别召开第二届董事会第五次会议、第二届监事会第五次会议，审议 通过了《关于续聘会计师事务所的议案》，同意公司继续聘请天健会计师事务所 （特殊普通合伙）（以下简称天健所）为公司及控股子公司2023年度审计机构， 聘期一年。该事项尚需提交公司股东大会审议通过后生效。现将相关事宜公告如 下： 一、拟续聘会计师事务所的基本信息 （一）机构信息 1、基本信息 2、投资者保护能力 截至2022年末，天健所累计已计提职业风险基金1亿元以上，购买的职业保 险累计赔偿限额超过1亿元，职业风险基金计提及职业保险购买符合财政部关于 《会计师事务所职业风险基金管理办法》等文件的相关规定。近三年在执业行为 相关民事诉讼中承担民事责任的情况： | 起诉（仲 | 被诉（被仲裁 | 诉讼（仲 | 诉讼（仲 | 诉讼（仲裁）结果 ...

Financial Performance - The company's total revenue for the year 2022 was CNY 1,415,288,702.33, with a year-on-year increase of 30.58% in overseas sales[12]. - In 2022, the company achieved operating revenue of 1.415 billion yuan, a growth of 24.43% compared to 2021[64]. - The net profit attributable to shareholders was 402 million yuan, an increase of 29.66% year-over-year[64]. - Basic earnings per share reached 1.08 yuan, reflecting a growth of 25.58% from the previous year[64]. - The total cash inflow from operating activities was 1.608 billion yuan, up 39.49% from the previous year[103]. - The net cash flow from operating activities reached 381 million yuan, a significant increase of 94.97% compared to 2021[103]. - The company reported a net cash increase of 646 million yuan, representing a 649.28% improvement year-over-year[103]. - The company's revenue for 2022 reached ¥1,415,288,702.33, representing a 24.43% increase compared to ¥1,137,447,250.97 in 2021[165]. - Net profit attributable to shareholders for 2022 was ¥402,088,234.73, a 29.66% increase from ¥310,101,397.04 in 2021[165]. Research and Development - The company increased R&D investment, with total R&D expenses reaching CNY 87.69 million in 2022, a 37.2% increase year-on-year[48]. - The number of R&D personnel increased by 61.64% to 375 in 2022[107]. - The company is focusing on the development of visual minimally invasive medical devices and has established a research and development technology platform for innovative products in this field[25]. - The company has committed to ongoing research and development of new medical technologies and products to enhance its competitive edge in the market[12]. - The company is actively involved in product development and manufacturing collaborations with innovative high-tech firms in various medical fields[41]. Market Expansion and Strategy - The company is focusing on expanding its market presence in overseas regions, with overseas sales contributing significantly to overall revenue growth[12]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by Q3 2023[199]. - The company has a clear strategy for market expansion and product innovation, aiming to strengthen its competitive edge in the industry[186]. - The company plans to implement a new digital marketing strategy aimed at increasing online sales by 40% in 2023[199]. Product Development and Innovation - Major products during the reporting period included components for home ventilators and cochlear implants, which are the company's primary offerings[40]. - The company is working on a large pulmonary function instrument with a flow measurement range of 0~±20L/S and a precision of ±0.15L/S, aimed at replacing imported products[119]. - The company has launched a large pulmonary function testing system, approved by the Guangdong Provincial Drug Administration on March 6, 2023, filling a gap in the domestic high-precision large pulmonary function instrument market[25]. - The company is focusing on enhancing its design capabilities and clinical impact through the development of high-performance visualization products for surgical applications[101]. Quality Management and Compliance - The company has established a comprehensive quality management system that meets the requirements of EU CE, US FDA, and NMPA regulations, enhancing product safety and effectiveness[26]. - The company emphasizes the importance of strict quality control standards throughout the production process to ensure product reliability[184]. - The company has built cleanrooms compliant with GMP standards for Class I, II, and III medical devices, enhancing its manufacturing capabilities[47]. Financial Position and Assets - Cash and cash equivalents at the end of 2022 amounted to ¥1,230,410,052.20, representing 36.31% of total assets, an increase from 22.08% at the beginning of the year[93]. - The total assets at the end of 2022 amounted to ¥3,388,446,632.86, a significant increase of 78.23% from ¥1,901,180,254.10 in 2021[165]. - The company's net assets attributable to shareholders reached ¥3,021,380,860.08, reflecting a 117.09% increase compared to ¥1,391,743,044.90 in 2021[165]. Operational Efficiency - The company has improved its IT information level and overall management capabilities, successfully launching a cost control reimbursement system and upgrading its human resources system[28]. - Operational efficiency improved, reducing costs by 12% through streamlined processes and automation[199]. - The company’s production capacity was positively impacted by the commissioning of the Huizhou production base and the expansion of the second phase in Malaysia[85]. Customer Relations and Satisfaction - Customer satisfaction ratings improved to 90%, reflecting a 5% increase from the previous year[199]. - The company aims to improve customer service quality by timely follow-ups on product after-sales and feedback[131]. Strategic Acquisitions - The company has initiated the development of a dual-material spiral tube extrusion technology for ventilators, with some specifications already in mass production[101]. - The company completed a strategic acquisition of a local competitor, enhancing its market share by 10%[199]. Industry Trends and Outlook - The global medical device market is projected to reach $59.45 billion by 2024, with a compound annual growth rate (CAGR) of 5.6%[179]. - The increasing health awareness among the population and the aging demographic are driving demand for home medical devices, presenting significant business opportunities[181]. - The domestic medical device industry is expected to see increased concentration due to industry upgrades and the implementation of the medical device registrant system[182].

Financial Performance - The net profit attributable to the parent company was CNY 108,394,751.90, an increase from CNY 67,017,224.47 in the previous period, representing a growth of approximately 62%[1] - The total comprehensive income attributable to the parent company was CNY 103,419,463.93, compared to CNY 63,941,727.19 in the previous period, indicating an increase of about 62%[1] - Basic and diluted earnings per share were both CNY 0.27, up from CNY 0.18 in the previous period, reflecting a growth of 50%[1] - The company's revenue for the reporting period reached ¥367,275,121.57, an increase of 29.24% compared to ¥284,171,341.73 in the same period last year[20] - Net profit attributable to shareholders was ¥108,394,751.90, reflecting a 61.74% increase from ¥67,017,224.47 year-over-year[20] - Net profit for Q1 2023 was CNY 108,394,751.90, compared to CNY 67,017,224.47 in Q1 2022, representing a 61.7% increase[44] Cash Flow - Cash inflow from operating activities totaled CNY 404,771,442.02, compared to CNY 339,480,490.18 in the previous period, marking an increase of approximately 19%[6] - The net cash flow from operating activities was CNY 62,825,635.11, significantly higher than CNY 29,853,643.99 in the previous period, representing a growth of over 110%[6] - The company reported a net increase in cash and cash equivalents of CNY 174,442,271.83, contrasting with a decrease of CNY 15,496,972.96 in the previous period[9] - The company received CNY 706,100,421.72 related to investment activities, a significant rise from CNY 39,936,515.20 in the previous period[6] - The net cash flow from investment activities was CNY 114,324,666.69, compared to a negative cash flow of CNY 117,815,481.68 in the previous period, showing a turnaround[6] - The company received tax refunds amounting to CNY 11,798,215.29, compared to CNY 7,815,535.11 in the previous period, reflecting an increase of approximately 50%[6] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,447,336,837.03, a 1.74% increase from ¥3,388,446,632.86 at the end of the previous year[20] - The total current liabilities decreased, with accounts payable dropping to CNY 143,430,712.32 from CNY 160,450,737.62, a reduction of approximately 10.6%[38] - The company's total liabilities decreased to CNY 322,536,513.02 from CNY 367,065,772.78, showing improved financial health[44] - The total equity attributable to shareholders reached CNY 3,124,800,324.01, up from CNY 3,021,380,860.08, reflecting growth in shareholder value[44] Operational Efficiency - The company completed the relocation of its registered office, which may facilitate operational efficiency[33] - Management expenses increased by 40.84% to ¥18,505,031.84, attributed to an increase in management personnel and average salaries[24] - The company reported a gross profit margin improvement, with gross profit for the period calculated at CNY 115,310,643.28, compared to CNY 74,195,240.62 in the previous year[44] Investments and Innovations - The company approved an investment of CNY 224,789,100 in the construction of the Meihua Chuangyi Building project using raised funds[34] - The company received two medical device registration certificates on March 6, 2023, valid until March 5, 2028, enhancing its product portfolio[35] - The company's investment income surged by 11,154.43% to ¥4,054,463.25, primarily from bank financial products[24] - Research and development expenses were CNY 20,709,769.49, an increase from CNY 17,150,460.88, indicating a focus on innovation[44] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[46]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于2023年4月 18日在巨潮资讯网（www.cninfo.com.cn）披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更深入全面地了解公司经营情况，公司定于2023年4月26 日（星期三）15:00-16:00在全景网举办"2022年度网上业绩说明会"，本次业绩 说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平 台"（https://ir.p5w.net）参与本次业绩说明会。 为充分听取投资者的意见和建议，提升交流的针对性，现就公司本次业绩说 明会提前向广大投资者公开征集问题，投资者可于2023年4月26日（星期三）12:00 前访问https://ir.p5w.net/zj/，或扫描下方二维码进入问题征集专题页面。公 司将在本次业绩说明会上，对投资者普遍关注的问题进行回答。在业绩说明会期 间，投资者仍可登陆活动界面进行互动提问。 （二维码放置） 证券代码：301363 证券简称：美好医疗 公告编号：20 ...

证券代码：301363 证券简称：美好医疗 公告编号：2023-037 深圳市美好创亿医疗科技股份有限公司 关于举行2022年度网上业绩说明会的公告 出席本次网上业绩说明会的人员有：公司董事长兼总经理熊小川先生，副 董事长兼副总经理袁峰先生，董事兼副总经理周道福先生，独立董事王建新先 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于2023年4月 18日在巨潮资讯网（www.cninfo.com.cn）披露了《2022年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更深入全面地了解公司经营情况，公司定于2023年4月26 日（星期三）15:00-16:00在全景网举办"2022年度网上业绩说明会"，本次业绩 说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平 台"（https://ir.p5w.net）参与本次业绩说明会。 为充分听取投资者的意见和建议，提升交流的针对性，现就公司本次业绩说 明会提前向广大投资者公开征集问题，投资者可于2023年4月25日（星期二）12:00 ...